LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China
Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...
Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion
Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...
Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...
Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development
B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO)...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
Merus’s Zenocutuzumab Receives Priority Review Status from FDA for Lung and Pancreatic Cancer Indications
Dutch biotechnology company Merus (NASDAQ: MRUS) has announced that the US Food and Drug Administration...
Lei Haichao Takes Over as Party Secretary of China’s National Health Commission
The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...
Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Tonghua Dongbao Pharmaceuticals Commences Phase IIa Trial for Dual-Targeted Gout Drug Candidate
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a China-based pharmaceutical company, has announced that the first patient...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
Henlius’ HER2 Dual-Targeted Therapy Gets Green Light for Global Phase III Trial by FDA
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced that it has received approval from...
Jacobio Pharma Applies for Approval of KRAS G12C Inhibitor Gecirasib in China
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced the submission of a New...
China’s CDE Gives Tacit Approval to Keymed Biosciences’ Alzheimer’s Drug CM383 for Clinical Trials
The Center for Drug Evaluation (CDE) has indicated on its website that China-based Keymed Biosciences...
Biocytogen and BioCopy AG Collaborate on TCR-Mimic Antibody Development for Cancer Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation...
CDE Seeks Public Comment on Latest Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), China’s regulatory body, is currently seeking public feedback on...
GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first...
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of...